Tarsus Pharmaceuticals, Inc. 8K

Tarsus Pharmaceuticals is acquiring iRenix Medical and its late-stage ocular antiseptic IRX-101 for $75 million upfront plus up to $490 million in milestones to expand its eye care and retina franchise.

On July 8, 2026, Tarsus Pharmaceuticals, Inc. announced it has acquired privately held iRenix Medical, Inc., obtaining its late-stage investigational ocular antiseptic IRX-101 for use in patients receiving intravitreal therapy, in a transaction providing approximately $75 million in upfront consideration (half cash, half Tarsus stock) plus up to $490 million in potential approval and commercial milestone payments; supported by positive Phase 2b/3 data and FDA-aligned development plans, Tarsus intends to initiate a Phase 3 trial of IRX-101 in the first half of 2027 to advance its eye care leadership strategy, particularly in retina, while hosting an investor call on July 8, 2026 to discuss the strategic and financial implications of the deal.

Filing Facts

CIK

1819790

Ticker

TARS

Form

8K

Source Type

fda

Accession

0001819790-26-000046

Alert Tier

8